Sciwind Biosciences APAC

Sciwind Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for metabolic diseases. The company's primary focus is on developing long-acting analogs of glucagon-like peptide-1 (GLP-1) and other incretin hormones to treat conditions such as type 2 diabetes, obesity, and metabolic dysfunction-associated steatohepatitis (MASH). Their lead candidate, ecnoglutide (XW003), is currently in late-stage clinical development, demonstrating significant potential in weight loss and glycemic control. Sciwind leverages its expertise in peptide engineering and formulation to create differentiated treatments with improved efficacy and patient convenience.